A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin

被引：1
|
作者：
Sciume, Mariarita [1 ]
Serpenti, Fabio [2 ]
Muratori, Simona [3 ]
Pravettoni, Valerio [4 ]
Ulivieri, Fabio Massimo [5 ]
Croci, Giorgio Alberto [6 ]
Migliorini, Anna Chiara [7 ]
Esposito, Andrea [8 ]
Goldaniga, Maria Cecilia [1 ]
Saporiti, Giorgia Natascia [1 ]
Galassi, Giulia [1 ]
Baldini, Luca [1 ,2 ]
Onida, Francesco [1 ,2 ]
Grifoni, Federica Irene [1 ]
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol Unit, Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Physiopathol & Transplantat, Dermatol Unit, Milan, Italy
[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Gen Med Immunol & Allergol, Milan, Italy
[5] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Bone Metab Unit, Nucl Med, Milan, Italy
[6] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Div Pathol, Milan, Italy
[7] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Serv Immunoematol & Trasfus, Lab Ematol, Milan, Italy
[8] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Radiol, Milan, Italy
来源：
CLINICAL CASE REPORTS | 2021年 / 9卷 / 02期
关键词：
bulky lymphadenopathy; midostaurin; purine analogue; systemic mastocytosis; ADULTS; NEOPLASMS; EFFICACY; SAFETY;
D O I：
10.1002/ccr3.3717
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Management of systemic mastocytosis is an emerging challenge which requires a multidisciplinary diagnostic approach and personalized treatment strategy. Midostaurin can rapidly reduce the disease burden, also in cladribine refractory cases.
引用
收藏
页码：978 / 982
页数：5
相关论文
共 50 条
  • [1] FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
    Kasamon, Yvette L.
    Ko, Chia-Wen
    Subramaniam, Sriram
    Ma, Lian
    Yang, Yuching
    Nie, Lei
    Shord, Stacy
    Przepiorka, Donna
    Farrell, Ann T.
    McKee, Amy E.
    Pazdur, Richard
    ONCOLOGIST, 2018, 23 (12) : 1511 - 1519
  • [2] Aggressive systemic mastocytosis presenting as rapidly progressive ascites, generalised lymphadenopathy and osteosclerosis
    Arun, Vijayalakshmi Aravindan
    Soni, Dipesh
    Bal, Amanjit
    Jain, Arihant
    BMJ CASE REPORTS, 2021, 14 (02)
  • [3] Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
    Szudy-Szczyrek, Aneta
    Bachanek-Mitura, Oliwia
    Gromek, Tomasz
    Chromik, Karolina
    Mital, Andrzej
    Szczyrek, Michal
    Krupski, Witold
    Szumilo, Justyna
    Kandula, Zuzanna
    Helbig, Grzegorz
    Hus, Marek
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (05) : 1 - 13
  • [4] Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis
    Pilkington, Hollie
    Smith, Sarah
    Roskell, Neil
    Iannazzo, Sergio
    FUTURE ONCOLOGY, 2022, 18 (13) : 1583 - 1594
  • [5] Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management
    Papayannidis, Cristina
    Federico, Vincenzo
    Fianchi, Luana
    Pregno, Patrizia
    Pugliese, Novella
    Romano, Alessandra
    Grifoni, Federica Irene
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2022, 14
  • [6] Aggressive systemic mastocytosis of colon and lymph node: A case report
    Xun-Ze, Shen
    Liu, Fang
    Lin, Chen
    Sun, Yi-Feng
    MEDICINE, 2023, 102 (21) : E33813
  • [7] Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
    Gotlib, Jason
    Kluin-Nelemans, Hanneke C.
    George, Tracy I.
    Akin, Cem
    Sotlar, Karl
    Hermine, Olivier
    Awan, Farrukh T.
    Hexner, Elizabeth
    Mauro, Michael J.
    Sternberg, David W.
    Villeneuve, Matthieu
    Labed, Alice Huntsman
    Stanek, Eric J.
    Hartmann, Karin
    Horny, Hans-Peter
    Valent, Peter
    Reiter, Andreas
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (26) : 2530 - 2541
  • [8] Aggressive systemic mastocytosis
    Inaoui, R
    Petit, B
    Jaccard, A
    Bertin, P
    Trèves, R
    JOINT BONE SPINE, 2003, 70 (01) : 64 - 66
  • [9] Aggressive systemic mastocytosis: midostaurin is safe, feasible and associated with durable response post-haploidentical allogeneic stem cell transplant
    Martynova, Anastasia
    Nael, Ali
    O'Neill, Caitlin
    Ramsingh, Giridharan
    Merchant, Akil
    Yaghmour, Bassam
    Yaghmour, George
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (05) : E139 - E141
  • [10] Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases
    Singh, Amritpal
    Al-Kali, Aref
    Begna, Kebede H.
    Litzow, Mark R.
    Larsen, Jeremy T.
    Sher, Taimur
    Abdelmagid, Maymona G.
    Farrukh, Faiqa
    Reichard, Kaaren K.
    Gangat, Naseema
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) : 630 - 637
12345